The company is under investigation for allegedly providing false and misleading information to investors regarding trial efficacy and safety data, which constitutes a breach of fiduciary duties and represents potential securities fraud.
The company is facing a class action lawsuit for securities violations, specifically for making false and misleading statements about product safety and efficacy while concealing adverse information. An FDA clinical hold on a key product candidate due to a tumor development in a trial participant represents a significant setback and regulatory concern.
Company faces class action lawsuit for alleged securities fraud following FDA clinical hold on two investigational gene therapies (RGX-111 and RGX-121), resulting in a 17.9% stock price decline on the announcement date.
The company faces a class action lawsuit alleging false and misleading statements about drug safety and efficacy. An FDA clinical hold on its lead candidate RGX-111 due to a serious adverse event (CNS tumor) in a trial participant resulted in an 18% stock price decline, indicating significant regulatory and commercial setbacks.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding clinical trial safety and efficacy data for its lead product candidate RGX-111, resulting in investor losses.
The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its RGX-111 therapy development, clinical trial results, and efficacy/safety profile. This represents significant legal and reputational risk to the company.
The company is accused of making false and misleading statements to investors about product candidate RGX-111, concealing negative efficacy and safety data. The discovery of an intraventricular CNS tumor in a study participant exposed the fraud, resulting in investor losses and a securities class action lawsuit.
The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about the efficacy and safety of its RGX-111 trial while making overwhelmingly positive assertions to investors, resulting in investor damages when the true details emerged.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding clinical trial data for its lead product candidate RGX-111. Investors claim they suffered damages when true details about efficacy and safety concerns entered the market.
Company faces class action lawsuit for concealing material adverse facts about RGX-111 gene therapy safety and efficacy. FDA placed clinical hold on the drug after a tumor was found in a trial participant, causing stock to drop 17.8% in one day.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding clinical trial safety and efficacy data for its lead product candidate RGX-111, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding the safety and efficacy of its RGX-111 clinical trial, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging it made false and misleading statements about its RGX-111 trial while concealing material adverse facts regarding efficacy and safety. This resulted in investor damages when the true details became public.
Company is defendant in a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding RGX-111 trial efficacy and safety data, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about its RGX-111 trial while concealing material adverse facts regarding efficacy and safety, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about its RGX-111 trial while concealing material adverse facts regarding efficacy and safety. This indicates potential fraud and investor harm.
The company is the subject of a securities class action lawsuit alleging it provided false and misleading statements about its RGX-111 trial while concealing material adverse facts regarding efficacy and safety. This represents significant legal and reputational risk to the company and its investors.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding the safety and efficacy of its RGX-111 clinical trial, resulting in investor damages.
Company is accused of providing false and misleading statements about RGX-111's efficacy and safety while concealing material adverse facts. An FDA clinical hold was placed on the drug candidate after a serious adverse event (CNS tumor) was discovered in a trial participant, resulting in a significant 17.8% single-day stock price decline and triggering securities litigation.
Articles that tag RGNX but are mainly about other companies.
Identified as a key company developing diabetic retinopathy therapies, but no specific product details or development stage information provided in the article.
Completed Phase II pivotal trials (ATMOSPHERE and ASCENT) for RGX-314 in wet AMD with topline data expected in 2026.
The company is mentioned as subject to a securities class action lawsuit by Rosen Law Firm, indicating alleged securities violations.
Company is subject to securities class action lawsuit; specific allegations not detailed in provided excerpt but implied similar misconduct involving misleading investor statements.
The company is subject to a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations and investor harm.
Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating allegations of investor harm through misrepresentation or non-disclosure of material information.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
